In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Type 1 selected

Type

Guidance programme

Showing 1 to 2 of 2

TitleTypeExpected publication date
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Technology appraisal guidance
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All